{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Silbereisen A"],"funding":["Vetenskapsrådet","Steering Group KI/Region Stockholm for Dental Research","Karolinska Institutet's Strategic Funds"],"pagination":["1288-1297"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12377945"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["52(9)"],"pubmed_abstract":["<h4>Background</h4>This study investigated the diagnostic potential of salivary triggering receptor expressed on myeloid cells (TREM)-1, peptidoglycan recognition protein 1 (PGLYRP1) and interleukin (IL)-1β for periodontitis patients and their ability to predict treatment outcome.<h4>Methods</h4>Systemically healthy, non-smokers with gingivitis (n = 31), stage III periodontitis (34 grade B: n = 34, grade C: n = 24) and healthy controls (n = 34) were recruited. Periodontitis patients (n = 42) underwent non-surgical periodontal treatment. Saliva was collected at baseline (T0) and post-treatment (T1, T3, T6). Biomarkers were measured using immunoassays. Periodontitis patients were categorised into responders (n = 19) and non-responders (n = 23) based on the number of residual pockets ≥ 5 mm w"],"journal":["Journal of clinical periodontology"],"pubmed_title":["TREM-1 Pathway Biomarkers for Classification of Periodontal Diseases and Monitoring of Treatment Response in Grade B and C Periodontitis."],"pmcid":["PMC12377945"],"funding_grant_id":["FoUI-966258","2021‐03528","2021-03528","FoUI-966140","FoUI-990869"],"pubmed_authors":["Emingil G","Bostanci N","Afacan B","Lira-Junior R","Silbereisen A","Ozturk OV"],"additional_accession":[]},"is_claimable":false,"name":"TREM-1 Pathway Biomarkers for Classification of Periodontal Diseases and Monitoring of Treatment Response in Grade B and C Periodontitis.","description":"<h4>Background</h4>This study investigated the diagnostic potential of salivary triggering receptor expressed on myeloid cells (TREM)-1, peptidoglycan recognition protein 1 (PGLYRP1) and interleukin (IL)-1β for periodontitis patients and their ability to predict treatment outcome.<h4>Methods</h4>Systemically healthy, non-smokers with gingivitis (n = 31), stage III periodontitis (34 grade B: n = 34, grade C: n = 24) and healthy controls (n = 34) were recruited. Periodontitis patients (n = 42) underwent non-surgical periodontal treatment. Saliva was collected at baseline (T0) and post-treatment (T1, T3, T6). Biomarkers were measured using immunoassays. Periodontitis patients were categorised into responders (n = 19) and non-responders (n = 23) based on the number of residual pockets ≥ 5 mm w","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-05-10T01:45:55.028Z","creation":"2026-04-08T01:25:00.602Z"},"accession":"S-EPMC12377945","cross_references":{"pubmed":["40528650"],"doi":["10.1111/jcpe.14195"]}}